Congressman Costello Named to U.S. House Energy & Commerce Committee
January 05, 2017
Congressman Ryan Costello (R, PA-06) was selected to serve on the U.S. House Energy & Commerce Committee which is vested with broad legislative jurisdiction including health, commerce, energy, environmental, and telecommunications policy. The Committee will play a pivotal role, particularly with respect to reforms to the Medicaid program, as Congress contemplates repealing and replacing the Affordable Care Act (ACA).
In a press statement, Congressman Costello expressed appreciation for the opportunity to work on policies that positively impact the jobs and quality of life for communities in Pennsylvania’s Sixth Congressional District, specifically pointing to innovation in health care and the life sciences.
Congressman Costello will join Congressman Mike Doyle (D, PA-14) and Congressman Tim Murphy (R, PA-18) as Pennsylvania representatives on the Committee. Pennsylvania was at risk of losing a seat on the Committee due to the retirement of Congressman Joe Pitts (R, PA-16). Congressman Costello’s selection preserves Pennsylvania’s representation with three of the 55 seats on the power Committee.
The Committee exercises oversight of the U.S. Department of Health & Human Services, the National Institutes of Health, and the Centers for Disease Control and Prevention. Of particular importance within the health policy space, the Committee has a direct stake in the following policy areas:
- Public health insurance (Medicare and Medicaid) and private health insurance
- Health information technology, privacy, and cybersecurity
- Public health issues
- Medical liability reform
- Mental health and drug abuse
- Biomedical research and development
- Regulation of food, drugs, and cosmetics
The Energy and Commerce Committee drove many of the key health policies enacted into law during the 114th Congress, including legislation repealing the sustainable growth rate and reforming the physician payment system; comprehensive reform to federal mental health policy; accelerating the discovery, development and delivery of medical innovations; and addressing the opioid epidemic.
During the previous Congress, in addition to conducting significant oversight of the ACA and the Medicaid program, the Committee held hearings and considered policy pertaining to the 340B drug pricing program, site neutral payment, telehealth, pediatric care, the hospital preparedness program, and public health threats.
Please contact Laura Stevens Kent, HAP's vice president, federal advocacy, with any questions.